GTX (01167) initiates the first clinical study of pan-KRAS inhibitor.

On November 11th, the Drug Clinical Trial Registration and Information Disclosure Platform showed that Jasco (01167) registered a multicenter, open-label Phase I/IIa study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of JAB-23E73 in late-stage solid tumors with KRAS gene mutations. This is the first clinical trial of this drug. According to the Pharma Cube database, pan-KRAS inhibitors are currently in early clinical research stages. Globally, there are only 7 pan-KRAS inhibitors in Phase I clinical trials, including Pfizer's PF-07934040, BeiGene's BG-53038, and Eli Lilly's LY4066434. In addition to JAB-23E73, Jasco has two other candidate drugs in development for KRAS inhibition, namely the KRAS G12C inhibitor golarece and the KRAS G12D inhibitor JAB-22000. Golarece has already applied for market approval and is undergoing priority review, while JAB-22000 is in the preclinical research stage.